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EDITORIAL
Pediatric  Crohn’s  Disease  and  Surgery:  Another  Tool
for the Treatment  of  a Complex  Disease
Doenc¸a de  Crohn  e  Cirurgia  Pediátrica:  Outra  Ferramenta  para  o  Tratamento
de  uma  Doenc¸a Complexa
Eunice TrindadePediatric  Gastroenterology  Unit,  Centro  Hospitalar  de  São  João,  Porto,  Portugal
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sThe  article  by  Lourenc¸o  et  al1 in  this  issue  of  GE  reports
the  experience  of  a  Portuguese  tertiary  center  on  surgery
in  pediatric  Crohn’s  disease.  Some  speciﬁcities  concerning
manifestations  and  management  of  pediatric  IBD  patients
should  be  highlighted  to  better  understand  different  aspects
of  this  problem.
Inﬂammatory  bowel  disease  (IBD),  a  chronic  and  relapsing
condition,  develops  during  childhood  or  adolescence  in  up
to  25%  of  patients.2,3
As  among  adults,  the  phenotypic  spectrum  in  Crohn’s  dis-
ease  (CD)  is  wide  but  with  some  particularities:  in  children
the  phenotype  is  more  often  extensive  and  aggressive  than  in
adults;  the  most  common  type  is  inﬂammatory,  followed  by
ﬁstulizing  and  structuring  disease;  also  unique  to  pediatric-
onset  disease  is  the  potential  for  linear  growth  impairment
and  delayed  sexual  development  already  at  disease  onset  or
as  a  complication  of  undertreated  inﬂammation.4
As  a  consequence  of  these  particularities  treatment
options  also  differ  from  adults  patients  and  are  an  indirect
demonstration  of  the  severity  of  the  disease.  It  is  therefore
clearly  important  to  diagnose  and  treat  pediatric  patients
early  in  order  not  only  to  induce  and  maintain  remission,
but  also  to  address  nutritional  deﬁciencies,  ensure  nor-
mal  growth,  avoid  complications  and  change  the  course
of  disease  if  possible,  especially  when  factors  suggestiveDOI of original article:
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tric  patients  require  long-term  maintenance  medication
immunomodulatory  and  biologics  agents).  Unfortunately
hese  medications  have  been  associated  with  several  side
ffects,  and  some  patients  may  have  to  discontinue  therapy
ue  to  treatment-related  complications  or  loss  of  efﬁcacy
reating  additional  problems.5
The  cumulative  risk  of  progression  to  complicated  CD
ooks  similar  to  adults,  but  because  of  early  onset  of  dis-
ase,  children  are  more  likely  to  have  undergone  surgery  by
oung  adulthood.  Pigneur,  et  al.  found  that  by  the  age  of  30
ears,  the  risk  of  surgical  resection  was  48  ±  5%  and  14  ±  2%
n  pediatric  and  adult  onset  CD,  respectively.6
It  is  evident  that  for  some  patients  surgery  is  inevitable
intestinal  perforation,  stenotic  ﬁbrosis  with  occlusion)  and
ometimes  done  in  an  emergency  setting  not  in  the  best
onditions.  For  a small  group  of  pediatric  patients  it  can
e  the  ﬁrst  option  of  treatment  and  done  in  a  planned  way
prepubertal,  localized  disease  to  terminal  ileum  and  growth
elay,  for  example).5
Minimally  invasive  surgery  is  being  increasingly  applied  in
ediatric  patients  with  IBD  and  proved  to  be  feasible,  safe
nd  effective  if  performed  by  surgeons  with  expertise  in  this
eld.7 Cosmetic  results  are  satisfactory,  a  very  important
ssue  in  patients  perspective.  This  is  also  the  experience  in
ur  center  with  12  CD  patients  submitted  to  laparoscopic
urgery  in  the  last  10  years  with  no  complications,  rapid
ecovery  and  good  functional  outcome  (unpublished  data).
It  is  very  well  known  that  recurrence  of  the  disease
fter  surgery  is  probable  and  only  a  matter  of  time,  with
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linical  and  endoscopic  recurrence  rates  of  2--25%  and
5--90%  respectively,  within  one  year.8 In  a  pediatric  pop-
lation  Hansen  et  al.  found  a  cumulative  clinical  recurrence
ate  at  1,  5 and  10  years  of  50%,  73%  and  77%  respectively.9
ith  this  in  mind  and  in  contrast  to  adult  CD  patients,
hildren  usually  start  maintenance  therapy  after  surgically
nduced  remission  despite  conﬂicting  results  in  the  litera-
ure  and  lack  of  pediatric  prospective  controlled  trials  on
he  prophylactic  effect  of  biologicals  and/or  immunomodu-
ators  after  surgery  for  CD.  The  recent  pediatric  guidelines
n  medical  management  of  CD  recommend  that  thiopurines
hould  be  used  as  ﬁrst  choice  drug  for  post-operative  main-
enance  therapy  and  that  anti-TNF-agents  can  be  an  option
n  selected  patients.5
Despite  this  proactive  attitude,  recurrence  at  the  site  of
nastomosis  still  occurs.  Because  clinical  signs  of  recurrence
ften  occur  in  an  advanced  stage  of  the  disease,  endoscopy
urveillance  is  mandatory  after  surgery  and  ileocolonoscopy
hould  be  performed  6--12  months  after  resection  to  guide
reatment  adjustment.5,10 In  POCER  study,  involving  adult
atients,  endoscopic  evaluation  showed  a  clear  advantage
f  systematic  evaluation  at  6  months  with  treatment  adapt-
on  for  low  and  high  risk  patients.11,12 This  is  the  strategy
hat  we  have  been  using  in  our  center  in  the  last  10  years.13
he  endoscopic  surveillance  and  step-up  in  medical  treat-
ent  according  to  recurrence  looks  even  more  important
n  the  pediatric  CD  patients  considering  their  young  age,
redictability  of  a  long  duration  of  the  disease  and  the
mperious  necessity  to  avoid  another  intestinal  resection.
e-scope  is  a  sensitive  issue  for  families  and  they  are  often
eluctant  to  subject  their  children  to  uncomfortable  bowel
reparation  and  anesthesia.  Sometimes  they  propose  to
ostpone  the  procedure  based  on  favorable  evolution  but
he  advantage  of  the  colonoscopy  should  be  explained.
In  the  retrospective  study  presented  by  Lourenc¸o et  al.,1
 patients  were  treated  by  classic  surgery  without  major
omplications  during  a  period  of  11  years.  The  results  con-
rm  that  surgery  was  safe,  inevitable  in  some  patients  and
cheduled  in  others.  The  indication  for  surgery  was  not  dif-
erent  from  the  results  of  other  pediatric  series.  The  pre  and
ostoperative  treatment  was  very  heterogeneous.  Clinical
ecurrence  after  surgery  was  seen  only  in  one  patient  but
he  follow-up  time  ranged  from  2  months  to  7  years.  In  this
ohort  of  patients  only  clinical  recurrence  was  evaluated
ecause  patients  were  not  submitted  to  endoscopic  surveil-
ance.  This  is  an  important  point  for  reﬂection  because
nastomotic  recurrence  is  silent  in  the  majority  of  patients
nd  should  be  appropriately  seen  by  endoscopy  considering
he  therapeutic  implications.  Seven  of  8  patients,  were  sub-
itted  to  azathioprine  and  inﬂiximab  after  surgery  and  it
ould  be  interesting  to  see  the  effect  of  these  medications
n  the  prevention  of  endoscopic  recurrence.  Because  of  the
mall  number  of  patients  involved  no  other  conclusions  can
e  drawn  and  this  is  also  the  problem  of  other  published
ediatric  series  reinforcing  the  importance  of  collaborative
tudies  among  centers.
Considering  the  complexity  of  pediatric  IBD
atients  they  should  be  treated  in  tertiary  pediatric
1E.  Trindade
astroenterology  centers  by  multidisciplinary  teams  includ-
ng  pediatric  gastroenterologist,  surgeon  with  special
nterest  on  IBD,  interventional  radiologist,  pathologists  and
nesthesiologists  able  to  offer  the  best  treatment  in  each
oment.  In  the  best  interest  of  the  patient  the  treatment
hould  always  be  individualized,  considering  the  beneﬁt-risk
f  each  option  and  based  on  the  existing  evidence.  As  pedi-
tricians  we  should  not  accept  ‘‘less  than  the  best’’  in  the
reatment  of  this  vulnerable  and  complicated  population.
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